Evidence map›Paper›PMID 38187711›Full record

ArticlebioRxiv : the preprint server for biology2023

Shieldin and CST co-orchestrate DNA polymerase-dependent tailed-end joining reactions independently of 53BP1-governed repair pathway choice.

Ashleigh King, Pia Reichl, Jean S Metson, Robert Parker, Daniella Munro, Catarina Oliveira, Jordan R Becker, Daniel Biggs, Chris Preece, Benjamin Davies and 1 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Ashleigh KingGenome Integrity laboratory, Medical Research Council Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, The University of Oxford, Oxford, UK.
Pia ReichlGenome Integrity laboratory, Medical Research Council Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, The University of Oxford, Oxford, UK.
Jean S MetsonGenome Integrity laboratory, Medical Research Council Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, The University of Oxford, Oxford, UK.
Robert ParkerCentre for ImmunoOncology, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Daniella MunroGenome Integrity laboratory, Medical Research Council Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, The University of Oxford, Oxford, UK.
Catarina OliveiraGenome Integrity laboratory, Medical Research Council Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, The University of Oxford, Oxford, UK.
Jordan R BeckerGenome Integrity laboratory, Medical Research Council Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, The University of Oxford, Oxford, UK.
Daniel BiggsWellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
Chris PreeceWellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
Benjamin DaviesWellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
J Ross ChapmanGenome Integrity laboratory, Medical Research Council Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, The University of Oxford, Oxford, UK.ORCID 0000-0002-6477-4254
University of Oxford · GBCentre for Human Genetics · GB

Funding

HORMAD1 directs the assembly of a meiotic-Shieldin complex in meiosis and cancerF32CA239339 · NCI · UNIVERSITY OF OXFORD · PI BECKER, JORDAN R · 2019 to 2020
$119k
Cancer Research UK 19270Medical Research Council MR/R017549/1NCI NIH HHS F32 CA239339Wellcome Trust
6 · The paper itself

Abstract

53BP1 regulates DNA end-joining in lymphocytes, diversifying immune antigen receptors. This involves nucleosome-bound 53BP1 at DNA double-stranded breaks (DSBs) recruiting RIF1 and shieldin, a poorly understood DNA-binding complex. The 53BP1-RIF1-shieldin axis is pathological in

Identifiers

PMID38187711
PMCPMC10769304
OpenAlexW4390082574

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.